The estimated Net Worth of Larry Spitcaufsky is at least 87.2 千$ dollars as of 21 November 2018. Larry Spitcaufsky owns over 1,280 units of Sonnet BioTherapeutics Inc stock worth over 33,819$ and over the last 7 years Larry sold SONN stock worth over 53,380$.
Sign up
Larry Spitcaufsky SONN stock SEC Form 4 insiders trading
Larry has made over 2 trades of the Sonnet BioTherapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Larry bought 1,280 units of SONN stock worth 2,355$ on 21 November 2018.
The largest trade Larry's ever made was selling 17,000 units of Sonnet BioTherapeutics Inc stock on 13 December 2017 worth over 53,380$. On average, Larry trades about 3,656 units every 69 days since 2017. As of 21 November 2018 Larry still owns at least 41,480 units of Sonnet BioTherapeutics Inc stock.
You can see the complete history of Larry Spitcaufsky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Larry Spitcaufsky's mailing address?
Larry's mailing address filed with the SEC is 16205 VIA DEL ALBA, PO BOX 891, , RANCHO SANTA FE, CA, 92067.
Insiders trading at Sonnet BioTherapeutics Inc
Over the last 8 years, insiders at Sonnet BioTherapeutics Inc have traded over 53,380$ worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth 290,512$ . The most active insiders traders include Pankaj Mohan、Donald J. Griffith、Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of 21,474$. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth 12,739$.
What does Sonnet BioTherapeutics Inc do?
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
What does Sonnet BioTherapeutics Inc's logo look like?
Complete history of Larry Spitcaufsky stock trades at Sonnet BioTherapeutics Inc
Sonnet BioTherapeutics Inc executives and stock owners
Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Pankaj Mohan Ph.D.,
Founder, Chairman. CEO & Pres -
Dr. Pankaj Mohan,
Founder, Chairman. CEO & Pres -
Jay Cross,
Chief Financial Officer -
Dr. John K. Cini Ph.D.,
Chief Scientific Officer & Co-Founder -
Dr. Richard T. Kenney FACP, M.D.,
Chief Medical Officer -
Manuel Dafonseca,
Head of Clinical Operations -
Dr. Richard T. Kenney,
Chief Medical Officer -
Susan Dexter,
Chief Technical Officer -
Frederick L Glick,
President -
Albert D. Dyrness,
Director -
Lori Mc Neill,
Director -
Gregory Evan Kraut,
Director -
Larry Spitcaufsky,
-
Richard Adams,
-
Neil G Kiefer,
Director -
Russell Jacob Page,
Director -
Keith J Johnson,
Director -
Troy Matson Shadoin,
Chief Accounting Officer -
Patrick Clay Harkleroad,
Chief Financial Officer -
Michael D Pruitt,
CEO, Chairman -
J Eric Wagoner,
Director -
John K. Cini,
Chief Scientific Officer -
Donald J. Griffith,
Director -
Susan Dexter,
Chief Technical Officer -
John Harry Iii Cross,
Chief Financial Officer -
Nailesh Bhatt,
Director -
Pankaj Mohan,
Chairman, President and CEO -
Terence Anthony Rugg,
Chief Medical Officer -
Raghu Rao,
Director -
Richard T Kenney,
Chief Medical Officer